Stock Alert: Anavex Life Sciences Jumps 16%

(RTTNews) - Share of Anavex Life Sciences Corp. (AVXL) are gaining over 16% on Thursday morning after the clinical-stage biopharmaceutical company announced results from Phase 2 study of Anavex 2-73 in patients with Parkinson disease.

AVXL is currently trading at $5.07, up $0.73 or 16.84%, on the Nasdaq.

Anavex Life Sciences announced results from the proof of concept Phase 2 controlled trial evaluating the safety, tolerability, and efficacy of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia.

The study found that ANAVEX 2-73 was safe and well tolerated in oral doses up to 50 mg once daily. The results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research computerized assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker of response to ANAVEX 2-73 (blarcamesine).

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More